Applied therapeutics announces acceptance of late-breaking abstract for oral presentation at the peripheral nerve society 2025 annual meeting

Late-breaking oral presentation to include full 12-month clinical data from inspire registrational phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension late-breaking oral presentation to include full 12-month clinical data from inspire registrational phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension
APLT Ratings Summary
APLT Quant Ranking